Cancer Pain: From Basic Research to Drug Discovery and Clinical Studies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".
Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 9032
Special Issue Editors
Interests: the capsaicin (vanilloid) receptor TRPV1; “thermoTRP” expression in cancer; TRP channels as oncotargets; TRP channels as tumor suppressors; sensory nerve-tumor interactions; oncothermia
Special Issues, Collections and Topics in MDPI journals
Interests: pharmacology of pain; analgesics; TRP channels; TRPA1; TRPV1
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer pain is one of the worst forms of chronic pain, with opioids being the mainstay of treatment. Unfortunately, most patients quickly develop opioid tolerance, leaving them with few therapeutic alternatives while battling this deadly disease. Thus, there is an urgent need to identify molecular mechanisms driving cancer pain to develop novel analgesic drugs. Most cancer pain occurs when the tumor destroys tissues or presses on nerves. However, cancer cells can also produce substances that make normally innocuous stimuli feel painful. Furthermore, therapeutic interventions can induce pain as an adverse effect, as exemplified by chemotherapy-induced peripheral neuropathy.
With this Special Issue, we aim to explore the current state of the cancer pain field, from basic research through to drug discovery and the development to clinical trials. Original research papers, reviews, clinical studies, and meta-analyses of clinical trials are all welcome to contribute.
Dr. Arpad Szallasi
Prof. Dr. Gabriela Trevisan
Dr. Andreea Dumele
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.